HIV-1 predisposed to acquiring resistance to maraviroc (MVC) and other CCR5 antagonists in vitro has an inherent, low-level ability to utilize MVC-bound CCR5 for entry.

Retrovirology

Volumn 8, Issue , 2011, Pages 89-

  Roche, Michael ^a   Jakobsen, Martin R ^b   Ellett, Anne ^b   Salimiseyedabad, Hamid ^b   Jubb, Becky ^b   Westby, Mike ^b   Lee, Benhur ^b   Lewin, Sharon R ^b   Churchill, Melissa J ^b   Gorry, Paul R ^b  

^a BURNET INSTITUTE   (Australia)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR5; CYCLOHEXANE DERIVATIVE; GLYCOPROTEIN GP 120; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; MARAVIROC; TRIAZOLE DERIVATIVE;

ANTIVIRAL RESISTANCE; ARTICLE; CELL LINE; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLISM; PHYSIOLOGY; PROTEIN BINDING; VIROLOGY; VIRUS ENTRY;

CELL LINE; CYCLOHEXANES; DRUG RESISTANCE, VIRAL; HIV ENVELOPE PROTEIN GP120; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV-1; HUMANS; PROTEIN BINDING; RECEPTORS, CCR5; TRIAZOLES; VIRUS INTERNALIZATION;

EID: 80355145632     PISSN: None     EISSN: 17424690     Source Type: Journal    
DOI: 10.1186/1742-4690-8-89     Document Type: Article

References (0)